ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 39 and 32 active MPM patients on therapy as of September 30, 2025 and 2024 and 100 and 1 active NSCLC patient(s) on ...
Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback